AQR Arbitrage’s BioMarin Pharmaceuticals BMRN Stock Holding History

AQR Arbitrage’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,422	Closed	-$636K	–	1125
2021 Q1	$636K	Sell	8,422 -2,166	-20%	-$177K	0.02%	510
2020 Q4	$909K	Buy	10,588 +6,286	+146%	+$498K	0.03%	471
2020 Q3	$327K	Sell	4,302 -3,088	-42%	-$312K	0.01%	456
2020 Q2	$911K	Sell	7,390 -23,366	-76%	-$2.32M	0.04%	295
2020 Q1	$2.54M	Sell	30,756 -12,125	-28%	-$1.04M	0.09%	210
2019 Q4	$3.61M	Sell	42,881 -34,470	-45%	-$2.6M	0.06%	225
2019 Q3	$5.21M	Sell	77,351 -34,123	-31%	-$2.63M	0.08%	188
2019 Q2	$9.41M	Buy	111,474 +52,156	+88%	+$4.46M	0.11%	161
2019 Q1	$5.27M	Sell	59,318 -55,253	-48%	-$5.12M	0.07%	199
2018 Q4	$9.76M	Buy	114,571 +87,502	+323%	+$8.32M	0.13%	144
2018 Q3	$2.63M	Buy	+27,069	New	+$2.7M	0.03%	221

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Arbitrage's BMRN Position: Q2 2021 in Review

AQR Arbitrage sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 8,422 shares — an estimated $636K sold.

AQR Arbitrage first reported a position in BMRN in Q3 2018 and held it in 11 quarters. The position peaked at $9.76M in Q4 2018. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

AQR Arbitrage reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
AQR Arbitrage sold 8,422 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $636K.
AQR Arbitrage first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 11 quarters.
AQR Arbitrage's BioMarin Pharmaceuticals position peaked at $9.76M in Q4 2018.
529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on AQR Arbitrage's 13F filing for Q2 2021, filed 16 Aug 2021.